Skip to content
Head to head

Corcept Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: CORT · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

CORT -15.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
CORTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price63.62515.02
Change today-2.09%-1.08%
1-year return-15.2%+22.0%
Market cap$6.96B$130.58B
52-week range28.66 – 126.38412.27 – 568.67
Valuation
P/E (TTM)47.8333.14
P/E percentile, own 5-yr range69th99th
P/B8.356.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)0.8215.32
Net profit (TTM)$89.74M$3.88B
Revenue (TTM)$963.65M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+64.0%+11.8%
Gross margin98.5%85.5%
Operating margin11.5%33.1%
Net margin16.5%30.7%
Free cash flow (TTM)$194.62M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership74.2%96.8%
Insider activity (12mo)10 buy / 35 sell28 buy / 22 sell
Short interest (% of float)8.4%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$166 (+161%)$624 (+21%)
StockVane view
StockVane Quant RatingD (23)C (68)
Company
Employees7306,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.